On November 5, 2021, the 4th China International Import Expo was held in Shanghai. China Grand Pharmaceutical and Healthcare Holdings Ltd. (hereinafter referred to as China Grand Pharmaceutical) attended with two innovative products - HeartLight X3, a medical device for the treatment of atrial fibrillation, and Novasight, a diagnostic device for coronary angiography and endovascular interventional surgery. The two medical devices are both appraised as sterling pioneers in their respective field of treatment and diagnosis.

China Grand Pharmaceutical's participation in the CIIE showcased its strength in the field of precision interventional diagnosis and treatment of cardiovascular and cerebrovascular diseases. China Grand Pharmaceutical offers a variety of high-end medical devices for cerebrovascular intervention, including the CoRISMA series of innovative medical devices for the treatment of heart failure, the shockwave intravascular lithotripsy system jointly developed with FastWave Medical Inc., Heartlight X3 for the treatment of atrial fibrillation and Novasight for coronary angiography and endovascular interventional surgery.

The precision interventional diagnosis and treatment of cardiovascular and cerebrovascular diseases embodies one of the core strategic fields of China Grand Pharmaceutical. In recent years, the company has frequently made efforts to deepen its innovative layout in five areas: vascular intervention, neuro intervention, structural heart disease, electrophysiology and heart failure, achieving tremendous progress for China Grand Pharmaceutical in building an international leading cardio-cerebrovascular precision interventional diagnosis and treatment platform.

As indicated by the exhibition representative of the China Grand Pharmaceutical, the company has always attached great importance to the research and development of innovative products and advanced technologies, meets the needs of patients, drives scientific and technological innovation, and increases investments in unsatisfied clinical needs to develop a technologically innovative high-end medical device cluster. The company comprehensively implements innovative strategies in the three areas, notably precise interventional diagnosis, treatment of cardiovascular and cerebrovascular diseases along with anti-tumor, and anti-virus as well as anti-infection, and adheres to the development concept of "integrating advantages, eliminating barriers and expanding global influence". Driven by the strategy of "independent research and development, global operation layout, dual-cycle operation and development", it has formed a new pattern of domestic and foreign dual-cycle linkage development and mutual promotion and is committed to becoming a technologically innovative international pharmaceutical company that is respected by doctors and patients.

About HeartLight X3 and Novasight:

HeartLight X3 is a revolutionary medical device that can achieve circular ablation for atrial fibrillation (AF) through laser. Its first- and second-generation products have been launched in Japan and Europe, and have been deployed by over 100 medical institutions, accumulating more than 10,000 clinical application cases and creating remarkable clinical effect. The third generation HeartLight combines the adjustable energy of traditional radiofrequency catheter ablation and the characteristics of point-to-point precise ablation. It also features simple cryoablation and short operation time, which greatly reduces the operator's learning curve. The product has been approved by the U.S. Food and Drug Administration (FDA) in May 2020. It is expected to be approved in China by 2025. The innovative product of NOVASIGHT Hybrid, which combines vascular ultrasound and optical coherence tomography, can display ultrasound and optical images at the same time, direction, axis and position. It is also the first intravascular ultrasound optical imaging fusion system approved by the U.S. FDA, with promising application prospects in the fields of coronary vascular imaging and endovascular interventional surgery. The product has been launched in the United States, Canada and Japan, and entered the green channel of special review of innovative medical devices in 2019. Clinical research is currently on-going, and it is expected to be launched in China in 2022. NOVASIGHT Hybrid had been recognized as the world's leading innovative interventional imaging system by the European heart journal of ESC in 2020, and has also been widely regarded as the world's only simultaneous coaxial single-operation dual-mode imaging system. It has made a revolutionary leap in coronary imaging technology.